-
Clinical Trials & Development1 month agoBeacon’s XLRP gene therapy set for filing after phase 3 win
Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
-
Capital, M&A & Industry Strategy1 month agoTelix to buy radiopharma rival ITM for $1.65bn upfront
Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
-
Regulatory Intelligence & Drug Approvals1 month agoCHMP backs Novo’s haemophilia A drug Frehemgo
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
-
Global Biotechnology & Pharmaceutical Markets1 month agoMPs seek probe into UK-US pharma deal’s impact on NHS
The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
-
Regulatory Intelligence & Drug Approvals1 month agoUltragenyx gets FDA nod for first Sanfilippo A gene therapy
Patients in the US with Sanfilippo syndrome type A have their first FDA-approved therapy, Ultragenyx Pharma's $3.9m one-shot gene therapy Fayuvi.
-
Capital, M&A & Industry Strategy1 month agoWhich biotechs have raised new VC financing this week?
This week's biggest biotech venture financings include sizeable rounds for Sling Therapeutics, Circle Pharma, and RegCell.
-
Clinical Trials & Development1 month agoBoehringer launches hub for patient experience data
Boehringer Ingelheim has launched a hub to help patient organisations gather and use patient experience data (PED) more effectively.
-
Capital, M&A & Industry Strategy2 months agoElectra sets terms for IPO, hoping to raise up to $347m
Electra Therapeutics has moved ahead with plans for an IPO, seeking to raise funds for its drug for the rare and life-threatening disease sHLH.
-
Global Biotechnology & Pharmaceutical Markets2 months agoGSK wagers $750m on Chimagen multiple myeloma therapy
GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
-
Regulatory Intelligence & Drug Approvals2 months agoFDA to decide on Takeda’s psoriasis blockbuster hope in Q1
The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
